The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

Since 2000, pharmaceutical manufacturing has increasingly moved offshore. Today, approximately 53% of brand drug products and 69% of generics have at least one manufacturer outside the United States.

The U.S. Food and Drug Administration (FDA) has issued warning letters to 30 telehealth companies citing false or misleading claims about compounded GLP-1 weight-loss products on their websites. The ...

The FDA PreCheck program, first announced in August, aims to streamline review of domestic pharmaceutical plants and eliminate unnecessary ‌regulatory requirements, in line with ⁠President Donald ...

Add Yahoo as a preferred source to see more of our stories on Google. A U.S. flag, a U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025 ...

Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year.

FDA's Plausible Mechanism Framework streamlines individualized therapy approvals for ultra-rare diseases.

Roughly half a year after introducing the new regulatory pathway, the FDA has greenlit the first drug under its ultra-speedy—and controversial—Commissioner's National Priority Voucher (CNPV) pilot ...

Incentives to bring vaccines to market are shrinking. Drugmakers are scaling back research investments and cutting jobs.

Estrogen patches, one of the most common forms of hormone therapy for women, are becoming harder to find, and some ...

The FDA began accepting requests Feb. 1 to participate in its PreCheck pilot program, an initiative aimed at streamlining regulatory review for new U.S.-based pharmaceutical manufacturing facilities.